LAURUS LABS Latest Share Price (LAURUSLABS)
TODAY IN ONE LINE
LAURUSLABS fell 2.7% on average volume, lagging Nifty's -1.6% move.
With a market cap of ₹1.08 L Cr., it trades at a P/E of 98.77. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LAURUS LABS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 19.4% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 18.7%
- ●FII AccumulationFII holding increased by 2.18% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 13.3% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 90.7x
- ●Rising Receivables vs SalesReceivables grew 22.1% outpacing sales growth of 10.2%
Latest LAURUS LABS News
What changed recently?
Recent events, corporate actions, and announcements.
LAURUS LABS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LAURUS LABS, framed against the sector median so the premium or discount is obvious at a glance.
LAURUS LABS trades at a P/E of 98.77× and P/B of 20.37×, against the Healthcare sector median P/E of 41.07×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LAURUS LABS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LAURUS LABS — derived from the latest tape, not yesterday's close.
LAURUS LABS last traded at ₹1,997.9 with an intraday range of ₹1,997.9–₹2,055 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1997.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2150.17 | +152.27 | +7.62% |
| R3 | 2093.07 | +95.17 | +4.76% |
| R2 | 2074.03 | +76.13 | +3.81% |
| R1 | 2035.97 | +38.07 | +1.91% |
| PIVOT | 2016.93 | 19.03 | 0.95% |
| CURRENT | 1997.90 | — | — |
| S1 | 1978.87 | -19.03 | -0.95% |
| S2 | 1959.83 | -38.07 | -1.91% |
| S3 | 1921.77 | -76.13 | -3.81% |
| S4 | 1864.67 | -133.23 | -6.67% |
LAURUSLABS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹2025.3–₹2055
Trading Below opening range, showing Bearishness
LAURUS LABS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LAURUS LABS — consolidated or standalone — with margins, YoY growth and key ratios inline.
LAURUS LABS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.08 L Cr. and reported EPS of ₹5.37.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 5,554 | 6,813 ▲ 22.7% |
| Sales Growth YoY %Derived | 10.18% | 22.67% |
| Other Income | 75 | 55 ▼ 26.8% |
| Total Income | 5,629 | 6,868 ▲ 22.0% |
| 2,478 | 2,695 ▲ 8.8% | |
| Gross ProfitDerived | 3,076 | 4,117 ▲ 33.9% |
| Gross Margin %Derived | 55.38% | 60.44% |
| 2,021 | 2,340 ▲ 15.8% | |
| EBITDA (Operating Profit)Derived | 1,055 | 1,778 ▲ 68.5% |
| OPM %Derived | 19.00% | 26.09% |
| 646 | 651 ▲ 0.7% | |
| Profit Before Tax (PBT) | 484 | 1,182 ▲ 144.0% |
| 130 | 292 ▲ 124.8% | |
| Effective Tax %Derived | 26.82% | 24.71% |
| Total Profit for Period | 358 | 890 ▲ 148.4% |
| Less: Non-controlling Interests | 0 | 1 ▲ 6650.0% |
| Net Profit (Owner's PAT)Derived | 358 | 889 ▲ 148.0% |
| Net Profit Margin %Derived | 6.45% | 13.05% |
| PAT Growth YoY %Derived | 123.18% | 148.04% |
| Earnings Per Share (EPS ₹) | 6.64 | 16.46 ▲ 147.9% |
| Diluted Shares Outstanding (Cr) | 54 | 54 ▲ 0.1% |
| Share of Profit from Associates/JVs | 4 | 0 ▼ 92.6% |
| Other Comprehensive Income (Net of Tax) | -4 | -6 ▼ 61.6% |
| Total Expenses (incl. D&A & Interest) | 5,145 | 5,686 ▲ 10.5% |
| Material Cost % of RevenueDerived | 43.73% | 41.02% |
| Employee Cost % of RevenueDerived | 12.96% | 13.14% |
| Other Cost % of RevenueDerived | 23.43% | 21.20% |
| Interest Coverage (x)Derived | 2.89x | 7.60x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,069 | 2,292 ▲ 10.8% | 2,832 ▲ 23.6% | 4,814 ▲ 70.0% | 4,936 ▲ 2.5% | 6,041 ▲ 22.4% | 5,041 ▼ 16.6% | 5,554 ▲ 10.2% | 6,813 ▲ 22.7% | |
| Sales Growth YoY %Derived | — | 10.77% | 23.55% | 69.99% | 2.54% | 22.39% | -16.55% | 10.18% | 22.67% | |
| Other Income | 29 | 16 ▼ 44.7% | 6 ▼ 63.3% | 24 ▲ 299.4% | 15 ▼ 35.3% | 6 ▼ 60.8% | 26 ▲ 339.0% | 75 ▲ 185.1% | 55 ▼ 26.8% | |
| Total Income | 2,098 | 2,308 ▲ 10.0% | 2,838 ▲ 22.9% | 4,837 ▲ 70.5% | 4,951 ▲ 2.4% | 6,047 ▲ 22.1% | 5,067 ▼ 16.2% | 5,629 ▲ 11.1% | 6,868 ▲ 22.0% | |
1,064 | 1,236 ▲ 16.2% | 1,413 ▲ 14.4% | 2,158 ▲ 52.7% | 2,194 ▲ 1.6% | 2,774 ▲ 26.5% | 2,432 ▼ 12.3% | 2,478 ▲ 1.9% | 2,695 ▲ 8.8% | ||
| Gross ProfitDerived | 1,005 | 1,056 ▲ 5.1% | 1,418 ▲ 34.3% | 2,655 ▲ 87.2% | 2,742 ▲ 3.3% | 3,266 ▲ 19.1% | 2,608 ▼ 20.1% | 3,076 ▲ 17.9% | 4,117 ▲ 33.9% | |
| Gross Margin %Derived | 48.59% | 46.09% | 50.09% | 55.16% | 55.55% | 54.07% | 51.75% | 55.38% | 60.44% | |
592 | 700 ▲ 18.3% | 854 ▲ 21.9% | 1,105 ▲ 29.4% | 1,319 ▲ 19.4% | 1,674 ▲ 26.9% | 1,831 ▲ 9.4% | 2,021 ▲ 10.4% | 2,340 ▲ 15.8% | ||
| EBITDA (Operating Profit)Derived | 413 | 356 ▼ 13.9% | 565 ▲ 58.6% | 1,551 ▲ 174.7% | 1,422 ▼ 8.3% | 1,592 ▲ 11.9% | 778 ▼ 51.2% | 1,055 ▲ 35.7% | 1,778 ▲ 68.5% | |
| OPM %Derived | 19.98% | 15.53% | 19.94% | 32.22% | 28.82% | 26.36% | 15.42% | 19.00% | 26.09% | |
205 | 252 ▲ 23.1% | 277 ▲ 9.7% | 273 ▼ 1.3% | 354 ▲ 29.5% | 489 ▲ 38.3% | 567 ▲ 16.0% | 646 ▲ 13.9% | 651 ▲ 0.7% | ||
| Profit Before Tax (PBT) | 237 | 120 ▼ 49.6% | 294 ▲ 145.2% | 1,301 ▲ 343.1% | 1,084 ▼ 16.7% | 1,109 ▲ 2.3% | 236 ▼ 78.7% | 484 ▲ 104.9% | 1,182 ▲ 144.0% | |
70 | 26 ▼ 62.8% | 38 ▲ 47.5% | 317 ▲ 727.6% | 251 ▼ 20.8% | 312 ▲ 24.2% | 68 ▼ 78.2% | 130 ▲ 90.6% | 292 ▲ 124.8% | ||
| Effective Tax %Derived | 29.40% | 21.70% | 13.06% | 24.39% | 23.20% | 28.16% | 28.83% | 26.82% | 24.71% | |
| Total Profit for Period | 168 | 94 ▼ 44.1% | 255 ▲ 172.3% | 984 ▲ 285.4% | 832 ▼ 15.4% | 793 ▼ 4.7% | 162 ▼ 79.5% | 358 ▲ 120.8% | 890 ▲ 148.4% | |
| Less: Non-controlling Interests | — | — | — | — | 5 | 3 ▼ 29.5% | 2 ▼ 48.2% | 0 ▼ 98.8% | 1 ▲ 6650.0% | |
| Net Profit (Owner's PAT)Derived | 168 | 94 ▼ 44.1% | 255 ▲ 172.3% | 984 ▲ 285.4% | 828 ▼ 15.9% | 790 ▼ 4.5% | 161 ▼ 79.7% | 358 ▲ 123.2% | 889 ▲ 148.0% | |
| Net Profit Margin %Derived | 8.10% | 4.09% | 9.01% | 20.44% | 16.77% | 13.08% | 3.18% | 6.45% | 13.05% | |
| PAT Growth YoY %Derived | — | -44.06% | 172.25% | 285.40% | -15.89% | -4.52% | -79.68% | 123.18% | 148.04% | |
| Earnings Per Share (EPS ₹) | 3.16 | 1.76 ▼ 44.3% | 4.78 ▲ 171.6% | 18.33 ▲ 283.5% | 15.40 ▼ 16.0% | 14.67 ▼ 4.7% | 2.98 ▼ 79.7% | 6.64 ▲ 122.8% | 16.46 ▲ 147.9% | |
| Diluted Shares Outstanding (Cr) | 53 | 53 ▲ 0.4% | 53 ▲ 0.4% | 54 ▲ 0.4% | 54 ▲ 0.1% | 54 ▲ 0.2% | 54 ▲ 0.1% | 54 ▲ 0.1% | 54 ▲ 0.1% | |
| Share of Profit from Associates/JVs | — | — | — | — | -0 | -3 ▼ 1473.5% | -6 ▼ 85.0% | 4 ▲ 166.2% | 0 ▼ 92.6% | |
| Other Comprehensive Income (Net of Tax) | 0 | -4 ▼ 18470.0% | -11 ▼ 209.7% | 5 ▲ 144.0% | 1 ▼ 79.4% | -6 ▼ 646.6% | -3 ▲ 49.0% | -4 ▼ 27.2% | -6 ▼ 61.6% | |
| Total Expenses (incl. D&A & Interest) | 1,861 | 2,188 ▲ 17.6% | 2,544 ▲ 16.3% | 3,536 ▲ 39.0% | 3,867 ▲ 9.4% | 4,938 ▲ 27.7% | 4,831 ▼ 2.2% | 5,145 ▲ 6.5% | 5,686 ▲ 10.5% | |
| Material Cost % of RevenueDerived | 51.30% | 54.33% | 56.99% | 49.01% | 45.98% | 42.99% | 48.06% | 43.73% | 41.02% | |
| Employee Cost % of RevenueDerived | 12.47% | 12.62% | 12.18% | 9.02% | 10.16% | 9.61% | 12.69% | 12.96% | 13.14% | |
| Other Cost % of RevenueDerived | 16.14% | 17.94% | 17.97% | 13.93% | 16.57% | 18.10% | 23.63% | 23.43% | 21.20% | |
| Interest Coverage (x)Derived | 3.61x | 2.17x | 4.21x | 19.74x | 11.44x | 7.68x | 2.15x | 2.89x | 7.60x |
LAURUS LABS segment analysis : revenue and profit mix.
Disclosed business segments at LAURUS LABS with their share of revenue and profit, switchable between consolidated and standalone reporting.
LAURUS LABS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LAURUS LABS.
Our AI distills the core fundamental drivers supporting LAURUS LABS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LAURUS LABS's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 128 (~3.1× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 9% would indicate weaker capital compounding.
LAURUS LABS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LAURUS LABS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LAURUS LABS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LAURUS LABS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LAURUS LABS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LAURUS LABS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LAURUS LABS stood at 43.3% of traded volume, against a 20-day average of 51.9%.
LAURUS LABS announcements: results, concalls, ratings, M&A.
Filings LAURUS LABS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LAURUS LABS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 150 documents below.
Trading Window
Laurus Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Investor Presentation
Laurus Labs Limited has informed the Exchange about Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Laurus Labs Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Laurus Labs Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Laurus Labs Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
LAURUS LABS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LAURUS LABS has declared, sequenced by announce and record date.
LAURUS LABS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LAURUS LABS: business, sector, key facts.
What LAURUS LABS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LAURUS LABS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LAURUSLABS, BSE: 540222.
Laurus Labs Limited is a prominent Indian pharmaceutical company specializing in the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) globally. Their core business revolves around providing generic APIs and oral solid dosage forms across a diverse range of therapeutic areas. This includes crucial medications for conditions such as HIV/AIDS (anti-retrovirals), diabetes, cardiovascular diseases, asthma, ophthalmic issues, cancer (oncology), gastrointestinal problems, and Hepatitis C.
The company's API production caters to a wide spectrum of therapeutic needs, demonstrating a strong commitment to addressing various healthcare challenges. Their focus on generics allows them to offer cost-effective alternatives to brand-name medications, increasing accessibility to essential medicines both domestically and internationally. This strategy contributes significantly to Laurus Labs' market position and competitive advantage.
Beyond APIs and finished formulations, Laurus Labs extends its expertise into the realm of biotechnology services. This diversification allows them to leverage their scientific capabilities in areas such as nutraceuticals, dietary supplements, alternative food proteins, and cosmeceuticals. The company's involvement in these fields showcases a forward-looking approach to expanding its product portfolio and tapping into emerging market segments.
Furthermore, Laurus Labs is engaged in the development of innovative enzymatic solutions for industrial biotechnology applications. This highlights their commitment to research and development, driving technological advancements within the broader biotechnology sector. Their work with animal origin-free recombinant proteins and enzymes for biopharmaceuticals signifies a dedication to producing high-quality, safe, and ethically sourced products for the pharmaceutical industry.
Finally, Laurus Labs offers comprehensive business support services specifically targeted at the pharmaceutical industry. The nature of these services isn't explicitly detailed but likely includes functions such as regulatory support, logistics, and potentially contract manufacturing or research collaborations. This completes their business model, rounding out their offerings with crucial support functions that strengthen their overall position within the pharmaceutical ecosystem.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LAURUS LABS (LAURUSLABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LAURUS LABS (LAURUSLABS)?
The current share price of LAURUS LABS (LAURUSLABS) is ₹1,997.90. Today, the stock has declined by ₹54.90 (2.67%), trading in a range of ₹1,997.90 to ₹2,055.00. The stock opened at ₹2,055.00 with a trading volume of 13,94,208 shares.
02Is LAURUS LABS stock a good investment for long-term?
LAURUS LABS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1.08 L Cr., P/E ratio of 98.77, ROE of 14.1%, and ROCE of 11.66%. The dividend yield stands at 0.1%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of LAURUS LABS stock?
The 52-week high price of LAURUS LABS (LAURUSLABS) is ₹2,065.20, while the 52-week low is ₹843.00. Currently trading at ₹1,997.90, the stock is 137% above its 52-week low and 3.26% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy LAURUS LABS stock at the current price?
Whether to buy LAURUS LABS stock at ₹1,997.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 98.77 and P/B ratio of 20.37. Today's performance shows a loss of 2.67%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of LAURUS LABS and when is the next dividend?
LAURUS LABS offers a dividend yield of 0.1%, which means for every ₹100 invested at the current price of ₹1,997.90, you can expect to receive approximately ₹0.10 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of LAURUS LABS?
LAURUS LABS's key financial metrics include: P/E Ratio: 98.77, P/B Ratio: 20.37, ROE: 14.1%, ROCE: 11.66%, Dividend Yield: 0.1%, EPS: ₹5.37, Book Value: ₹100.53, and Debt-to-Equity: 0.38. The company's market cap stands at ₹1.08 L Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is LAURUS LABS stock performing today in the market?
LAURUS LABS stock opened at ₹2,055.00 and is currently trading at ₹1,997.90, showing a decline of ₹54.90 (2.67%). The intraday high is ₹2,055.00 and low is ₹1,997.90. The trading volume stands at 13,94,208 shares, indicating strong market participation today.
08What is the P/E ratio of LAURUS LABS and what does it indicate?
LAURUS LABS has a Price-to-Earnings (P/E) ratio of 98.77, which means investors are willing to pay 98.77 for every ₹1 of earnings. With an EPS of ₹5.37, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about LAURUS LABS (LAURUSLABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.